Merck & Co., Inc. (MRK) Says Clot Preventer has Bleeding Risk  
1/20/2011 7:01:19 AM

Reuters -- Merck & Co's experimental blood clot preventer vorapaxar can cause bleeding in patients who previously suffered a stroke, the drugmaker confirmed on Wednesday. Merck said last week that an independent committee to monitor clinical trials of the drug determined that vorapaxar was inappropriate for patients with a history of strokes.